|

Decoy-resistant interleukin-18 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: DR-18, Engineered IL-18 Variant ST-067, Engineered Interleukin-18 Variant ST-067, ST 067, ST-067 +1 more

Pipeline

Phase 1: 1

Top Sponsors

  • Fred Hutchinson Cancer Center1

Indications

  • Recurrent Myelodysplastic Syndrome1
  • Recurrent Acute Myeloid Leukemia1
  • Myelodysplastic Syndrome1
  • Acute Myeloid Leukemia1
  • Cancer1

Seattle, Washington1 trial

DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial

Fred Hutch/University of Washington Cancer Consortium

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.